<p>ArriVent BioPharma（納斯達克股票代碼：AVBP）週三公佈了季度財報數據。公司報告稱，本季度每股收益（EPS）為（$0.65），與市場預期的（$0.65）相符，據 Zacks 報道。</p>
<p>獲取 <strong>ArriVent BioPharma</strong> 的警報：</p>
<h2>ArriVent BioPharma 股價下跌 0.4%</h2>
<p>AVBP 週四下跌$0.09，報$23.86。公司交易量為 110,115 股，低於平均交易量 122,485 股。ArriVent BioPharma 過去 12 個月的最低價為$14.35，最高價為$25.95。公司 50 天移動平均價為$19.57，200 天移動平均價為$19.16。</p>
<h2>分析師升級和降級</h2>
<p>AVBP 成為多份分析師報告的研究對象。Oppenheimer 重申對 ArriVent BioPharma 的 “表現優異” 評級，並在週四的一份報告中發佈了$35.00 的目標股價。HC Wainwright 在 6 月 6 日週四的一份報告中重申了 “買入” 評級，併發布了$25.00 的目標股價。根據 MarketBeat.com 的數據，五位分析師對該股票給予買入評級，目前市場普遍評級為 “買入”，平均目標股價為$30.40。</p>
<p><strong>查看我們對 ArriVent BioPharma 的最新股票報告</strong></p>
<h2>ArriVent BioPharma 公司簡介（獲取免費報告）</h2>
<p>ArriVent BioPharma，Inc 是一家在美國從事為患有癌症患者提供未滿足醫療需求的藥物的識別、開發和商業化的臨牀階段生物製藥公司。公司還致力於開發和商業化針對非小細胞肺癌（NSCLC）和其他實體腫瘤的靶向癌症療法。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們比 ArriVent BioPharma 更喜歡的股票</li>
<li>投資者如何找到最好的便宜股息股票</li>
<li>Michael Burry 的阿里巴巴賭注及更廣泛的市場影響</li>
<li>如何使用 MarketBeat Excel 股息計算器</li>
<li>Jeff Brown 的 Exegesis AI 股票推薦</li>
<li>交易量異常的股票：如何實時找到異常交易量股票</li>
<li>沃倫·巴菲特的賭注：為什麼伯克希爾哈撒韋買入了 Ulta 股票</li>
</ul>
<p><em>此即時新聞警報由 Narrative Science 技術和 MarketBeat 的財務數據生成，以向讀者提供最快速和最準確的報道。本故事在發佈前經 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 您的 iPhone 意外之財？（來自 InvestorPlace）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc4"/></p>
<h2>您現在是否應該投資$1,000 在 ArriVent BioPharma？</h2>
<p>在考慮投資 ArriVent BioPharma 之前，您需要聽到這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂尖和表現最佳的研究分析師以及他們向客户推薦的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户現在購買的股票...而 ArriVent BioPharma 不在名單上。</p>
<p>雖然 ArriVent BioPharma 目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

納斯達克綜合指數

納斯達克 100 科技市值加權指數

AVBP

<p>阿睿飛生物製藥（NASDAQ:AVBP）宣佈其季度盈利結果，報告每股收益符合分析師的預期。儘管如此，股價下跌了 0.4%，交易價為 0.86 美元。分析師們重申了公司的目標價格，Oppenheimer 和 HC Wainwright 均發出買入評級。目前股票的共識評級為 “買入”，平均目標價為 1.40 美元。阿睿飛專注於開發針對癌症的靶向療法，特別是非小細胞肺癌</p>

<p>ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.65) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.65), Zacks reports.</p>
<div class="lb-trans"><p>ArriVent BioPharma（納斯達克股票代碼：AVBP）週三公佈了季度財報數據。公司報告稱，本季度每股收益（EPS）為（$0.65），與市場預期的（$0.65）相符，據 Zacks 報道。</p>
</div><p>Get <strong>ArriVent BioPharma</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>ArriVent BioPharma</strong> 的警報：</p>
</div><h2>ArriVent BioPharma Stock Down 0.4 %</h2>
<div class="lb-trans"><h2>ArriVent BioPharma 股價下跌 0.4%</h2>
</div><p>AVBP traded down $0.09 on Thursday, hitting $23.86. 110,115 shares of the company traded hands, compared to its average volume of 122,485. ArriVent BioPharma has a 12-month low of $14.35 and a 12-month high of $25.95. The company has a 50 day moving average of $19.57 and a 200-day moving average of $19.16.</p>
<div class="lb-trans"><p>AVBP 週四下跌$0.09，報$23.86。公司交易量為 110,115 股，低於平均交易量 122,485 股。ArriVent BioPharma 過去 12 個月的最低價為$14.35，最高價為$25.95。公司 50 天移動平均價為$19.57，200 天移動平均價為$19.16。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師升級和降級</h2>
</div><p>AVBP has been the topic of several analyst reports. Oppenheimer reaffirmed an &#34;outperform&#34; rating and issued a $35.00 target price on shares of ArriVent BioPharma in a report on Thursday. HC Wainwright reissued a &#34;buy&#34; rating and issued a $25.00 target price on shares of ArriVent BioPharma in a report on Thursday, June 6th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of &#34;Buy&#34; and an average price target of $30.40.</p>
<div class="lb-trans"><p>AVBP 成為多份分析師報告的研究對象。Oppenheimer 重申對 ArriVent BioPharma 的 “表現優異” 評級，並在週四的一份報告中發佈了$35.00 的目標股價。HC Wainwright 在 6 月 6 日週四的一份報告中重申了 “買入” 評級，併發布了$25.00 的目標股價。根據 MarketBeat.com 的數據，五位分析師對該股票給予買入評級，目前市場普遍評級為 “買入”，平均目標股價為$30.40。</p>
</div><p><strong>Check Out Our Latest Stock Report on ArriVent BioPharma</strong></p>
<div class="lb-trans"><p><strong>查看我們對 ArriVent BioPharma 的最新股票報告</strong></p>
</div><h2>ArriVent BioPharma Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>ArriVent BioPharma 公司簡介（獲取免費報告）</h2>
</div><p>ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.</p>
<div class="lb-trans"><p>ArriVent BioPharma，Inc 是一家在美國從事為患有癌症患者提供未滿足醫療需求的藥物的識別、開發和商業化的臨牀階段生物製藥公司。公司還致力於開發和商業化針對非小細胞肺癌（NSCLC）和其他實體腫瘤的靶向癌症療法。</p>
</div><h2>Recommended Stories</h2>
<ul>
<li>Five stocks we like better than ArriVent BioPharma</li>
<li>How Investors Can Find the Best Cheap Dividend Stocks</li>
<li>Michael Burry's Alibaba Bet and the Broader Market Implications</li>
<li>How to Use the MarketBeat Excel Dividend Calculator</li>
<li>Jeff Brown's Exegesis AI Stock Picks</li>
<li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li>
<li>Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock</li>
</ul>
<div class="lb-trans"><h2>推薦故事</h2>
<ul>
<li>五隻我們比 ArriVent BioPharma 更喜歡的股票</li>
<li>投資者如何找到最好的便宜股息股票</li>
<li>Michael Burry 的阿里巴巴賭注及更廣泛的市場影響</li>
<li>如何使用 MarketBeat Excel 股息計算器</li>
<li>Jeff Brown 的 Exegesis AI 股票推薦</li>
<li>交易量異常的股票：如何實時找到異常交易量股票</li>
<li>沃倫·巴菲特的賭注：為什麼伯克希爾哈撒韋買入了 Ulta 股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由 Narrative Science 技術和 MarketBeat 的財務數據生成，以向讀者提供最快速和最準確的報道。本故事在發佈前經 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Your iPhone windfall? (From InvestorPlace)(Ad)</p>
<div class="lb-trans"><p>→ 您的 iPhone 意外之財？（來自 InvestorPlace）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc4" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9178&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in ArriVent BioPharma right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資$1,000 在 ArriVent BioPharma？</h2>
</div><p>Before you consider ArriVent BioPharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 ArriVent BioPharma 之前，您需要聽到這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ArriVent BioPharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂尖和表現最佳的研究分析師以及他們向客户推薦的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户現在購買的股票...而 ArriVent BioPharma 不在名單上。</p>
</div><p>While ArriVent BioPharma currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 ArriVent BioPharma 目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

ArriVent BioPharma（納斯達克：AVBP）公佈收益結果